Close Menu

People in the News

Aug 01, 2019

Fluidigm: Jonathan Day

Fluidigm has appointed Jonathan Day as VP of commercial operations, Americas. Day was most recently VP of sales and support, Americas, for Agena Bioscience. Previously, he held roles of increasing responsibility at Thermo Fisher Scientific. Day also previously worked for Affymetrix.

Aug 01, 2019

Thrive: David Daly

Thrive has appointed David Daly as CEO and to its board of directors. Daly joins the firm with more than 25 years of leadership. Prior to Thrive, Daly served as senior VP and general manager of commercial operations at Illumina. Prior to Illumina, Daly served as general manager and chief commercial officer at Foundation Medicine. Before working at Foundation Medicine, Daly led the oncology business unit at Life Technologies, served as CCO at Clarient, and held roles at Roche Diagnostics and Abbott Laboratories.

Jul 30, 2019

Genomics England: Chris Wigley

Chris Wigley has been appointed as CEO of Genomics England, effective October 1. He will replace current interim CEO Sir Mark Caulfield, who will remain the firm's chief scientist. Wigley will join Genomics England, which is wholly owned by the UK's Department of Health & Social Care, from QuantumBlack, a machine learning and artificial intelligence company, where he was chief operating officer. Prior to that, he was a partner at McKinsey, and before that, a diplomat with the British Foreign Office.

Jul 29, 2019

Health Network Laboratories: Xinjing Wang

Xinjing Wang has been appointed director of clinical genomics at Health Network Laboratories. Wang is currently associate director of the genetics laboratory, department of pediatrics at the University of Oklahoma Health Sciences Center. He also was director of a CLIA-certified genetic lab at the National Eye Institute, part of the National Institutes of Health, and he was medical director of molecular diagnostics laboratory, department of laboratory medicine and pathology at the University of Minnesota. 

Jul 29, 2019

Yourgene Health: John Brown

John Brown has been appointed as a non-executive director of Yourgene Health. He will be the senior independent director on the board. Currently, Brown is a senior independent director at BioCity and at Acacia Pharma. He is also chairman of Cell Therapy Catapult and of Synpromics.

Jul 29, 2019

Pacific Biosciences: Stephen Turner

Pacific Biosciences Chief Technology Officer Stephen Turner has become a senior research fellow at nematode screening firm NemaMetrix of Eugene, Oregon. Turner, a cofounder of PacBio, holds a PhD in physics from Cornell University and will maintain his current position at the firm.

Jul 26, 2019

CureMatch: Yekaterina Khotskaya

San Diego-based digital health irm CureMatch has appointed Yekaterina Khotskaya as VP of clinical operations. Khotskaya is a former precision oncology scientist and fellow at the MD Anderson's Institute for Personalized Cancer Therapy.

Jul 25, 2019

Fluidigm: Bill Colston

Fluidigm has appointed Bill Colston to its board of directors. Colston has served as president of iCarbonX since March. He joined the company as chief operating officer in April 2018 following its acquisition of his prior company. He is also on the board of iCarbonX. Prior to this, he was cofounder and CEO of HealthTell. He was also previously the scientific founder and CEO of QuantaLife, which originally developed the technlogy behind Bio-Rad's droplet digitial PCR products.

Jul 25, 2019

OncoCell: Marc Stapley

Molecular diagnostic firm OncoCell MDx has appointed Marc Stapley to its board of directors. Stapley currently serves as president and CEO of Helix and is a member of the Glaukos board of directors. Prior to Helix, Stapley served as executive VP at Illumina. At Illumina, he also served as the chief administrative officer and CFO. Before Illumina, he held executive finance positions at Pfizer and other large multinational companies. 

Jul 24, 2019

Arcis Biotechnology: Steve Howell

Arcis Biotechnology, a nucleic acid sample prep provider, has appointed Steve Howell as non-executive chairman of the board. Howell will replace Paul Foulger, who was serving as chairman of the board on an interim basis. Howell is a professor of commercial innovation at King's College, London, a position he has held since 2015. He founded Innova Partnerships in 2006, and has previously served as director of business development at Alere and research director at Unipath.

Jul 24, 2019

OncoCyte: Melinda Griffith

OncoCyte has appointed Melinda Griffith to its board of directors. Griffith is a senior executive who has led business development, licensing, and legal activities for a number of diagnostic, device and pharmaceutical companies. In addition to her board appointment for OncoCyte, she currently serves as vice president of strategic alliances and chief legal counsel for the Parker Institute for Cancer Immunotherapy an dis chair of the board of directors for intenrational health non-profit Thrive Networks.

Prior to this, Griffith held a number of executive roles at public and private biotech companies, including GE Healthcare's Clarient Cancer Laboratories, Genelabs Technologies, CardioDx, Tethys BioSciences, and Axys Pharmaceuticals, Cetus Corporation, and Hoffmann La-Roche.

Jul 22, 2019

Hologic: Kevin Thornal

Marlborough, Massachusetts-based Hologic said in a filing with the US Securities and Exchange Commission that effective July 29, it has appointed Kevin Thornal, the president of its medical aesthetics division, as president of its diagnostics division.

Jul 18, 2019

Tristan Orpin, Randy Armant, Richard Shippy, Sascha Drewlo

NIPT startup Cradle Genomics of San Diego announced its management team this week.

Tristan Orpin is the firm's CEO. Previously, he was chief commercial officer and executive VP of clinical genomics at Illumina. Prior to that, he held executive positions at Sequenom and at Bio-Rad Laboratories. Orpin has a BSc in genetics and biochemistry from the University of Melbourne.

Randy Armant is a cofounder and the firm's VP of research. He is a professor of obstetrics and gynecology at Wayne State University. Armant holds a PhD in developmental biology and biochemistry from Virginia Tech.

Richard Shippy is a cofounder and the company's VP of commercial. Previously, he was the senior director of strategic product marketing in reproductive and genetic health at Illumina. Before that, he held management positions in clinical market development at Affymetrix and at GE Healthcare. Shippy holds an MSc in biochemistry from Northern Illinois University.

Sascha Drewlo is a cofounder and Cradle's VP of development. He holds a PhD in molecular and cell biology from the German Sport University Cologne and an MSc in microbiology and genetics from the University of Münster.

Jul 18, 2019

Sam Samad

Westbrook, Maine-based Idexx Laboratories has appointed Sam Samad to its board of directors. Samad currently serves as senior VP and CFO at Illumina. Prior to joining Illumina, Samad held multiple senior leadership positions at Cardinal Health from 2009 to 2017, including senior VP and corporate treasurer. 

Jul 18, 2019

Mark McClellan

San Francisco-based life science and health data firm Seer has appointed Mark McClellan to its board of directors. McClellan currently serves as a professor of business, medicine, and health policy at Duke's Duke-Margolis Center for Health Policy. Prior to Duke, McClellan served as administrator of the Centers for Medicare & Medicaid Services and commissioner at the US Food and Drug Administration. 

Jul 18, 2019

Kirk Wojno

OncoCell MDx, an immunogenomics company developing noninvasive molecular diagnostic assays, has named Kirk Wojno as chief medical officer. Wojno is former head of urologic pathology at the University of Michigan; at Ascension Health System; and AmeriPath, a division of Quest Diagnostics. He has more than 30 years in medical practice and most recently served as the chief of pathology and laboratory services and director of cinical research for the Comprehensive Urology practice in Royal Oak, Michigan.

Jul 17, 2019

J. Wallace Parce

Ontera, a Santa Cruz, California-based firm developing silicon-based nanopore diagnostics, has appointed J. Wallace Parce to its advisory board. He has cofounded and held senior positions at a number of life science technology companies including Nanosys, Caliper Technologies, and Molecular Devices. 

Parce was an associate professor at Wake Forest University's medical school and also received his doctorate from that university.

Jul 12, 2019

Alexander Mackinnon

Alexander “Craig” Mackinnon has become the inaugural director of the Division of Genomics, Diagnostics, and Bioinformatics in the Department of Pathology at the University of Alabama at Birmingham School of Medicine. He will lead ongoing efforts to establish a Precision Diagnostic Laboratory at UAB. 

Mackinnon is a board-certified anatomical and molecular genetic pathologist. Previously, he was associate professor in the Department of Pathology at the Medical College of Wisconsin, where he directed the Clinical and Translational Research Laboratory, which developed multiple sequencing-based panels targeting variants in both DNA and RNA. 

Jul 10, 2019

Keng Hsu

Keng Hsu has stepped down from the board of Yourgene to improve the balance of executive and non-executive directors and to allow him to focus on business development in Asia. Yourgene plans to add non-executive directors to its board in the near future.

Jul 09, 2019

Christopher Thibodeau

OncoCell MDx has appointed Christopher Thibodeau as chief operating officer. Prior to OncoCell MDx, Thibodeau served as COO at MDxHealth. Before MDxHealth, he held various positions at Agendia, Numira Biosciences, LabCorp's US LABS, and Roche Diagnostics' Ventana Medical Systems 

Jul 03, 2019

Steven Averbuch

Steven Averbuch has joined Caris Life Sciences' scientific advisory board. Averbuch recently retired from the role of vice president and head of precision medicine in the translational medicine division of R&D at Bristol-Myers Squibb. During his tenure, Averbuch spearheaded the Pharmacodiagnostics Center of Excellence, which led to the application of BMS' precision medicine strategy across all therapeutic areas. Prior to this, Averbuch oversaw corporate-wide strategic initiatives for translational and targeted medicine at BMS. He also served as head of early global clinical research at the company. Averbuch also previously held leadership roles with Merck Research Laboratories and AstraZeneca, and held academic appointments at Mount Sinai School of Medicine and the US Public Health Service School of Medicine.

Jul 03, 2019

Jonathan Genzen

ARUP Laboratories appointed Jonathan Genzen as its chief operating officer effective July 1. Genzen has held a number of positions since starting at ARUP in January 2013. He served as its chemistry section chief and medical director for its automated core laboratory, laboratory automation, and Farmington clinical laboratory, among other responsibilities. Prior to joining ARUP, Genzen was a faculty member in the Department of Pathology and Laboratory Medicine at Weill Cornell Medical College.

Jul 02, 2019

Troy Cox

Troy Cox has joined Sophia Genetics' board of directors. Cox previously was CEO of Foundation Medicine, which was acquired by Roche last year. Prior to that he was senior vice president and an officer at Genentech. He has also held executive and senior positions with UCB BioPharmaceuticals, Sanofi-Aventis, and Schering-Plough.

Jul 02, 2019

Grace Colón

CareDx has appointed Grace Colón to its board of directors.  Colón currently served as president, CEO, and director of InCarda Therapeutics. She is also executive chairman of ProterixBIo and is on the board of Cocoon Biotech. Colón previously served on the boards of Paradigm Diagnostics and PerceptiMed. Colón has also served as a partner at New Science Ventures and held various leadership roles at Intrexon, Gilead Sciences, and Affymetrix. She will succeed Amy Abernethy on CareDx's board. 

Jul 01, 2019

David Rubin, Timothy Harris

David Rubin and Timothy Harris informed OpGen that they would be leaving the company's board, effective June 30. OpGen disclosed the resignations in a document filed with US Securities and Exchange Commission on July 1. Both had been on OpGen's board since 2015. The company said there had been no disagreement with Rubin or Harris leading to their resignations. 

Pages

Retraction Watch reports that a paper was pulled because it refers to a gene that doesn't exist in mice.

Researchers were able to generate fertilized northern white rhinoceros eggs, according to Mashable.

Former Orig3n employees raise concerns about its testing at Bloomberg Businessweek.

In PLOS this week: microRNA expression changes in hepatocellular carcinoma, real-time PCR-based approach for diagnosing schistosomiasis, and more.